美國(guó)Glycominds www.glycominds.com
Glycominds公司通過分析針對(duì)每種疾病的特異性聚糖抗體生物標(biāo)記物來區(qū)分這些疾病。例如檢測(cè)多重硬化癥的生物標(biāo)記物，就是通過錨定在微孔滴定板上的糖分子固定8種檢測(cè)用的聚糖抗體。Glycominds為炎癥性腸道疾病提供了基于3種聚糖抗體標(biāo)記物的經(jīng)濟(jì)的檢驗(yàn)方法，并且計(jì)劃進(jìn)一步開發(fā)用于其他炎癥性疾病的檢測(cè)。

Glycominds Ltd. holds extensive knowledge and experience in the field of glycomics, utilized for the discovery and development of unique glycan biomarkers which enable high-value medical diagnostics. Glycominds is developing and commercializing a new class of novel blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.

Autoimmune Decisions™
Our leading products are the IBDX®, a blood tests for Inflammatory Bowel Disease (IBD) diagnostics and Crohn's Disease severity assisting physicians in early and quick diagnosis and in fitting the appropriate course of treatment for CD patients, and the gMS™ a blood test for the prediction of patients with clinical isolated syndrome suggestive of MS converted to clinically definitive Multiple Sclerosis. This powerful test will enable physicians to take post-CIS treatment decisions.
We believe in advanced autoimmunity tests that will improve the quality of life for millions of patients